[go: up one dir, main page]

DK3302483T3 - Farmaceutiske sammensætninger og anvendelse deraf - Google Patents

Farmaceutiske sammensætninger og anvendelse deraf Download PDF

Info

Publication number
DK3302483T3
DK3302483T3 DK16799287.4T DK16799287T DK3302483T3 DK 3302483 T3 DK3302483 T3 DK 3302483T3 DK 16799287 T DK16799287 T DK 16799287T DK 3302483 T3 DK3302483 T3 DK 3302483T3
Authority
DK
Denmark
Prior art keywords
application
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
DK16799287.4T
Other languages
English (en)
Inventor
Zhongzhou Liu
Chongdong Fu
Bin Shi
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Application granted granted Critical
Publication of DK3302483T3 publication Critical patent/DK3302483T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16799287.4T 2015-05-25 2016-05-24 Farmaceutiske sammensætninger og anvendelse deraf DK3302483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/079650 WO2016187767A1 (en) 2015-05-25 2015-05-25 Pharmaceutical compositions and use thereof
PCT/CN2016/083098 WO2016188399A1 (en) 2015-05-25 2016-05-24 Pharmaceutical compositions and use thereof

Publications (1)

Publication Number Publication Date
DK3302483T3 true DK3302483T3 (da) 2020-06-15

Family

ID=57392304

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16799287.4T DK3302483T3 (da) 2015-05-25 2016-05-24 Farmaceutiske sammensætninger og anvendelse deraf

Country Status (26)

Country Link
US (1) US20180153890A1 (da)
EP (1) EP3302483B1 (da)
JP (1) JP6878309B2 (da)
KR (1) KR102573278B1 (da)
CN (1) CN107613984B (da)
AU (1) AU2016269304B2 (da)
BR (1) BR112017024126B8 (da)
CA (1) CA2985379C (da)
CY (1) CY1123408T1 (da)
DK (1) DK3302483T3 (da)
ES (1) ES2796575T3 (da)
HR (1) HRP20200935T1 (da)
HU (1) HUE050697T2 (da)
LT (1) LT3302483T (da)
MX (1) MX380547B (da)
MY (1) MY188169A (da)
PH (1) PH12017502148A1 (da)
PL (1) PL3302483T3 (da)
PT (1) PT3302483T (da)
RS (1) RS60355B1 (da)
RU (1) RU2712187C2 (da)
SG (1) SG10202106375UA (da)
SI (1) SI3302483T1 (da)
SM (1) SMT202000281T1 (da)
TW (1) TWI714588B (da)
WO (2) WO2016187767A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090324A1 (en) 2016-11-18 2018-05-24 Hutchison Medipharma Limited Method of treating solid tumors
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药(上海)有限公司 呋喹替尼制剂及其应用
CN114085214A (zh) * 2020-08-25 2022-02-25 和记黄埔医药(上海)有限公司 索凡替尼杂质及其制备方法和用途
US20220073642A1 (en) * 2020-09-07 2022-03-10 Hutchison Medipharma Limited Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
ES2401335T3 (es) * 2004-03-15 2013-04-18 Ptc Therapeutics, Inc. Derivados de carbolina útiles en la inhibición de la angiogénesis
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药(上海)有限公司 一种化合物及其晶体
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用

Also Published As

Publication number Publication date
RS60355B1 (sr) 2020-07-31
HK1245113A1 (zh) 2018-08-24
ES2796575T3 (es) 2020-11-27
CA2985379A1 (en) 2016-12-01
CY1123408T1 (el) 2021-12-31
SG10202106375UA (en) 2021-07-29
BR112017024126B1 (pt) 2023-04-11
KR20180006422A (ko) 2018-01-17
TW201641108A (zh) 2016-12-01
WO2016187767A1 (en) 2016-12-01
HRP20200935T1 (hr) 2020-09-18
CN107613984A (zh) 2018-01-19
JP2018515587A (ja) 2018-06-14
EP3302483A4 (en) 2019-02-27
KR102573278B1 (ko) 2023-09-01
MX380547B (es) 2025-03-12
WO2016188399A1 (en) 2016-12-01
TWI714588B (zh) 2021-01-01
BR112017024126A2 (pt) 2018-07-31
EP3302483B1 (en) 2020-04-15
CN107613984B (zh) 2021-04-30
PH12017502148A1 (en) 2018-05-28
RU2712187C2 (ru) 2020-01-24
BR112017024126B8 (pt) 2023-05-09
AU2016269304B2 (en) 2021-04-15
CA2985379C (en) 2023-08-01
MY188169A (en) 2021-11-24
JP6878309B2 (ja) 2021-05-26
AU2016269304A1 (en) 2017-11-30
PL3302483T3 (pl) 2020-11-02
LT3302483T (lt) 2020-06-25
US20180153890A1 (en) 2018-06-07
SI3302483T1 (sl) 2020-07-31
SMT202000281T1 (it) 2020-07-08
RU2017139880A (ru) 2019-06-25
MX2017014880A (es) 2018-04-10
RU2017139880A3 (da) 2019-10-03
EP3302483A1 (en) 2018-04-11
PT3302483T (pt) 2020-06-16
NZ737544A (en) 2021-06-25
HUE050697T2 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3513809A4 (en) MEDICAL COMPOSITION
DK3655017T3 (da) Farmaceutisk sammensætning
SI4070787T1 (sl) Farmacevtske formulacije
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3603620T3 (da) Liposomsammensætning og farmaceutisk sammensætning
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3399978T3 (da) Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3583943T3 (da) Farmaceutisk sammensætning
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf